Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

Blood

Volumn 128, Issue 1, 2016, Pages E1-E9

  McKerrell, Thomas ^a,c   Moreno, Thaidy ^d   Ponstingl, Hannes ^a   Bolli, Niccolo ^a,e   Dias, João M L ^f   Tischler, German ^a   Colonna, Vincenza ^a,g   Manasse, Bridget ^b   Bench, Anthony ^b   Bloxham, David ^b   Herman, Bram ^h   Fletcher, Danielle ^h   Park, Naomi ^a   Quail, Michael A ^a   Manes, Nicla ^a,c   Hodkinson, Clare ^c   Baxter, Joanna ^c   Sierra, Jorge ⁱ   Foukaneli, Theodora ^b   Warren, Alan J ^b,c,j,k   Chi, Jianxiang ^l,m   Costeas, Paul ^l,m   Rad, Roland ^n,o   Huntly, Brian ^b,c,j,k   Grove, Carolyn ^p,q   Ning, Zemin ^a   Tyler Smith, Chris ^a   Varela, Ignacio ^d   Scott, Mike ^b,c   Nomdedeu, Josep ⁱ   Mustonen, Ville ^a   Vassiliou, George S ^a,c   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d University of Cantabria   (Spain)

^e UNIVERSITY OF MILAN   (Italy)

^f The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (Spain)

^g INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^h AGILENT TECHNOLOGIES   (United Kingdom)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l The Center for the Study of Haematological Malignancies   (Cyprus)

^m Center for the Study of Haematological Malignancies   (Cyprus)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^p SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^q UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA; MIXED LINEAGE LEUKEMIA PROTEIN; CARRIER PROTEIN; DIAPH2 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; FLT3 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; MLL PROTEIN, HUMAN; ONCOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CHROMOSOME REARRANGEMENT; CHROMOSOME SUBSTITUTION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC PROCEDURE; DNMT3A R882 GENE; FUSION GENE; GENE IDENTIFICATION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENOMICS; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; INDEL MUTATION; KARYOGENE; MAJOR CLINICAL STUDY; MLL DIAPH2 GENE; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; ZYGOSITY; CLINICAL TRIAL; FEMALE; GENETICS; HEMATOLOGIC NEOPLASMS; LEUKEMIA, MYELOID; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; PROCEDURES;

CARRIER PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENOMICS; HEMATOLOGIC NEOPLASMS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION;

EID: 84977674608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-683334     Document Type: Article

References (42)

1. Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27(9):1820-1825.
2. Bolli N, Manes N, McKerrell T, et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica. 2015;100(2):214-222.
3. Luthra R, Patel KP, Reddy NG, et al. Nextgeneration sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: Applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3): 465-473.
4. Kuo FC, Dong F. Next-generation sequencing based panel testing for myeloid neoplasms. Curr Hematol Malig Rep. 2015;10(2):104-111.
5. Spencer DH, Abel HJ, Lockwood CM, et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013;15(1):81-93.
6. Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA. 2009;106(31):12950-12955.
7. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: A novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731-2739.
8. Gronseth CM, McElhone SE, Storer BE, et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015;121(17):2900-2908.
9. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552-555.
10. McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports. 2015;10(8): 1239-1245.
11. Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol. 2006;135(4): 438-449.
12. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAM tools. Bioinformatics. 2009;25(16):2078-2079.
13. Fischer A, Vázquez-García I, Illingworth CJ, Mustonen V. High-definition reconstruction of clonal composition in cancer. Cell Reports. 2014; 7(5):1740-1752.
14. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in N Engl J Med. 2013;369(1): 98]. N Engl J Med. 2013;368(22):2059-2074.
15. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
16. Cammenga J, Horn S, Bergholz U, et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005;106(12):3958-3961.
17. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010;24(9): 1656-1657.
18. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
19. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627, quiz 3699.
20. Fröhling S, Schlenk RF, Breitruck J, et al; AML Study Group Ulm. Acute Myeloid Leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
21. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-4335.
22. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
23. Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA. 1998;95(5):2390-2395.
24. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20(15):3254-3261.
25. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5):796-804.
26. De Braekeleer E, Douet-Guilbert N, Morel F, et al. FLNA, a new partner gene fused to MLL in a patient with acute myelomonoblastic leukaemia. Br J Haematol. 2009;146(6):693-695.
27. Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165-2176.
28. Medvedev P, Stanciu M, Brudno M. Computational methods for discovering structural variation with next-generation sequencing. Nat Methods. 2009;6(suppl 11):S13-S20.
29. Abel HJ, Duncavage EJ. Detection of structural DNA variation from next generation sequencing data: A review of informatic approaches. Cancer Genet. 2013;206(12):432-440.
30. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
31. Goode BL, Eck MJ. Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem. 2007;76:593-627.
32. DeWard AD, Alberts AS. Microtubule stabilization: formins assert their independence. Curr Biol. 2008;18(14):R605-R608.
33. Zhu XL, Liang L, Ding YQ. Over expression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis. 2008; 23(11):1041-1047.
34. Liźarraga F, Poincloux R, Romao M, et al. Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res. 2009;69(7):2792-2800.
35. Favaro PM, de Souza Medina S, Traina F, Bassères DS, Costa FF, Saad ST. Human leukocyte formin: A novel protein expressed in lymphoid malignancies and associated with Akt. Biochem Biophys Res Commun. 2003;311(2): 365-371.
36. Favaro PM, Traina F, Vassallo J, et al. High expression of FMNL1 protein in T non-Hodgkin's lymphomas. Leuk Res. 2006;30(6):735-738.
37. Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67(16): 7565-7571.
38. Döhner H, Estey EH, Amadori S, et al; European Leukemia Net. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
39. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14): 3932-3941.
40. Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442-454.
41. Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152-165.
42. Gale RE, Lamb K, Allen C, et al. Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015; 33(18):2072-2083.